## Amendments to the Abstract

Please amend the Abstract beginning at line 3 on page 35 and ending at line 25 on page 35, of the specification, as follows:

The invention relates to an in vitro method for inducing a conformational transition in proteins, whereas said conformational the transition results resulting in an increased content of \(\mathbb{B}\)-sheet secondary structure, the method-comprising the steps of: a) providing a conversion buffer; b) adding a solution of lamellar lipid structures that comprise negatively charged lipids to the conversion buffer; c) adding protein molecules to the conversion buffer; d) forming a sample mixture from the conversion buffer, the added lipids and protein molecules; e) establishing a conversion temperature in the sample mixture; and f) exposing the sample mixture of step d) to the conversion temperature according to step e) for a time sufficient to form conformationally transitioned proteins. By this The method forms water soluble complexes of lamellar lipidic structures and conformationally transitioned proteins are formed, the conformationally transitioned proteins being having oligomeric &sheet intermediate structures. Amyloidogenic aggregates may be produced from the complexes by actively destroying the lamellar lipid structures. Such proteins The aggregates may be involved in neurodegenerative diseases like Transmissible Spongiform Encephalopathy (TSE), Alzheimers disease, Multiple Sclerosis and Parkinsons The methods and water soluble complexes are useful disclosure disease. comprises the use of the proteins produced by the method, e.g., for exploiting the various aspects of the PrPc to PrPsc conversion[[;]] as well as for the development of new diagnostic TSE-tests and potential therapeutics or prophylactics against TSE such as Creutzfeldt-Jakob disease in human.

(Fig.7)